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Objectives: To determine the effectiveness of a structured multidisciplinary non-surgical obesity therapy program on the basis of
a temporary low-calorie-diet for 12 weeks, and additional intervention modules to enhance nutritional education, to increase
physical activity and to modify eating behavior.
Design: Prospective multicenter observational study in obese individuals undergoing a medically supervised outpatient-based
52-week treatment in 37 centers in Germany.
Subjects: A total of 8296 participants with a body mass index (BMI) of 430kgm
 2 included within 8.5 years.
Measurements: Main outcome measures were body weight loss, waist circumference (WC), blood pressure, quality of life and
adverse events.
Results: In females, initial body weight was reduced after the 1-year-intervention by 19.6kg (95% confidence intervals
19.2–19.9kg) and in males by 26.0kg (25.2–26.8) according to per protocol analysis of 4850 individuals. Intention-to-treat
(ITT) analysis revealed a weight reduction of 15.2kg (14.9–15.6) in females and 19.4kg (18.7–20.1) in males. Overall, the
intervention resulted in mean reduction in WC of 11cm; it reduced the prevalence of the metabolic syndrome by 50% and the
frequency of hypertension from 47 to 29% of all participants (ITT, all Po0.001). The beneficial effects could be documented for
up to 3 years and comprised significant improvement of health-related quality of life. The incidence of adverse effects was low;
the only event repeatedly observed and possibly related to either the intervention or the underlying disease was biliary disorders.
Conclusion: The present non-surgical intervention program is a highly effective treatment of obesity grades I–III and obesity-
related diseases, and therefore, could be a valuable basis for future weight maintenance strategies required for sustained success.
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Introduction
Obesity is a chronic disease and a major health problem,
with increases worldwide over a few decades at an alarm-
ing rate.
1 European obesity prevalence ranges from
4.0–36.5%, depending on gender and geographical regions,
2
approximating the prevalence of obesity among US adults,
which has reached 31% in men and 33% in women.
3 The
consequences are enormous. Obesity is now recognized as
the most important risk factor contributing to the health
burden of the world, as it is associated with numerous
complications, including type 2 diabetes, hypertension,
cardiovascular disease, non-alcoholic fatty liver disease,
arthritis, depression and, as shown more recently, certain
cancers.
4,5 Obesity is estimated to reduce average life
expectancy and is causing a major economic burden on
health insurance.
6,7
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www.nature.com/ijoThis detrimental situation is worsened by the fact that the
available obesity prevention and treatment tools are far from
satisfactory. Either they lack validated effectiveness or they
are not sufficiently established and accepted in the medical
community, or they are invasive and side effects have not
been thoroughly evaluated. Health insurances frequently
refuse reimbursement of costs, which limits the availability
of particular programs for large parts of the afflicted
population. Two major reasons for insurers’ reluctance to
pay for most programs include the insufficient scientific
evidence for the efficiency of particular intervention
measures and the cost-benefit justification of primary and
additional ongoing costs for obesity treatment.
In the last few years, reports have shown that bariatric
surgery is effective; however, the acceptance rate is
unknown. Non-surgical weight-loss programs might have
a higher acceptance rate, but have been poorly studied in a
systematic manner or often failed to achieve and maintain
desirable body weights.
8 One of the few exceptions is the
study by Wadden and Frey
9 who showed that such a program
is still effective after 5 years follow-up in 50% of participants
who maintained medically significant weight loss of 5% or
greater. In the present study, we aimed to further study the
effectiveness of non-surgical approaches and analyzed a
52-week intervention program, which is medically super-
vised, out-patient-based and available in most major cities
in Germany. Analysis of clinical data from all participants
(48000) over 8.5 years in 37 obesity centers in Germany
shows that a multidisciplinary non-surgical weight loss
program can be highly effective in reducing weight and
weight-associated risk factors for up to 3 years.
Materials and methods
Intervention program
The present study was an investigator-initiated analysis
of data from obese individuals who underwent a defined
multidisciplinary non-surgical weight loss program
(OPTIFAST52 (OF52) program, franchise holder Nestle ´ Inc.,
Vevey, CH).
The German OF52 program that covers 12 month of
intervention was established in 1999. Data from all partici-
pants since 1999 until 2008 from 37 German centers were
collected and included in an unselected manner. A previous
6-month-version had been launched a decade earlier in
Germany, the US and other countries, and showed high
initial success rates in selected centers over 6 months.
8,9
However, intention-to-treat (ITT) data regarding weight loss
and reductions in comorbidities over 12 months from all
centers conducting the program nationwide are not available
from the 6-month-version. Only self-reported data sets from
telephone interviews are available beyond 6 months.
9
Therefore, we conducted a first comprehensive evaluation
of treatment success of the German OF52 program after
12 months.
In contrast to the previous 6-month-version, the actual
OF52 program contains an additional intensive weight loss
maintenance training in the second half of the treatment
year, focusing primarily on weight regain prevention and
improvement of long-term success rates. Weight, waist
circumference (WC), laboratory values, blood pressure and
other clinical data were monitored regularly during the
52-week program. Only patients of OF52 were included in
the present study. OF52 consists of a five-phase lifestyle
modification program designed for 52 weeks, including meal
replacement for 12 weeks and based on four modules
(psychology, medicine, dietetics and exercise), imparted by
a team of trained qualified health professionals such as
psychologists, medical doctors, dietitians/nutritionists and
physical therapists.
10–14 During the program, closed groups
of 8–15 persons meet weekly for about three and a half hours
per session. The five program phases included (i) a 1-week-
introduction time to check inclusion and exclusion criteria
indicated below; (ii) a 12-week-period of low-calorie diet
(LCD; 800kcal per day) during which participants consume
formula diet exclusively (daily consumption of five packets
at 160kcal each of meal replacement products dissolved in
300ml water each; Optifast 800 formula, Nestle ´ Inc.),
accompanied by 12 medical examinations, 12 exercise units,
two behavior therapy lessons and two nutrition counselings;
(iii) a 6-week-refeeding phase, during which solid food is
reintroduced and formula diet is stepwise replaced by normal
diet without change of total energy intake, accompanied by
six medical examinations, six exercise units, two behavior
therapy lessons and six nutrition counselings; (iv) a 7-week-
stabilization phase in which energy intake is stepwise,
enhanced to an individual level that allows weight stabiliza-
tion, accompanied by three medical examinations, four
exercise units, four behavior therapy lessons and three
nutrition counselings; and (v) a 26-week-maintenance phase
in which nutritional education and behavior modification is
intensified to learn coping strategies and to achieve long-
term weight control, accompanied by six medical examina-
tions, 13 exercise units, 22 behavior therapy lessons and five
nutrition counselings. The German OF52 uses a much more
structured approach during the 52-week program than the
26-week Optifast-program in the US.
9
Study population
At program start, all patients agreed in written form to
provide their data anonymously. The inclusion criteria
comprised an age 18–70 years, body mass index (BMI)
430kgm
 2, no comorbidities prohibiting participation in
the program such as bedridden, cardiac or pulmonal
insufficiency class III/IV according to the New York Heart
Association, cardiac arrythmia, recent myocardial infarction,
malignant disease, pregnancy or lactation, hypothyroidism,
severe eating disorder and severe depression. Other comor-
bidities such as arterial hypertension, hypercholesterolemia,
diabetes and other metabolic disorders were registered either
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laboratory findings. Arterial hypertension was defined as a
systolic blood pressure 4140mmHg or a diastolic blood
pressure 490mmHg, hypertriglyceridemia as serum trigly-
ceride levels 4200mgdl
 1, hypercholesterolemia as serum
low-density lipoprotein cholesterol levels 4155mgdl
 1,
fatty liver disease was assumed if alanine transaminase
(ALT) was elevated (~435 #450) in the absence of signs
of liver disease of other origin and diabetes as pathological
fasting serum glucose levels of 4126mgdl
 1. Patients and
family doctors were informed and recommended to treat the
comorbidities according to guidelines; however, most parti-
cipants had no drug treatment on a regular basis. Medical
treatment was adapted during the program by the physician
of the center in conjunction with the family doctors. All
patients had to deliver a medical certificate for the necessity
of treatment by their family doctor. Exclusion criteria
included development of severe cardiopulmonary disease,
malignant disease or pregnancy during participation.
Recruitment and data analysis
A defined data set was collected prospectively from each
participant consisting of baseline data at start (T0), data of
week 26 (T1) and at program termination at week 52 (T2).
The data sets were collected mandatory in all German
centers and transferred to a database, using special software
provided by the program supplier (Optisoft; Nestle ´ Inc.). The
1-year-data were transmitted to an independent institute
for data management (Campana and Schott, Frankfurt,
Germany). The institute maintained anonymity of all patient
data in the central database. During the 8.5 years evaluation
period, 8894 matched the inclusion criteria, of which 8296
participants could be included into analysis (Figure 1).
Clinical parameters (age, sex, weight, height, WC, blood
pressure) and laboratory parameters in serum (fasting
glucose, triglycerides, total cholesterol/low-density lipopro-
tein–cholesterol, high-density lipoprotein cholesterol, ALT,
g-glutamyl-transpeptidase, sodium, potassium, creatinine
and uric acid) were assessed. We calculated BMI, relative
Matching th eeligibility criteria,
allocated to intervention (n=8894)
Allocation
Excluded (n=582)
♦ Secure data transfer issues (n=244)
♦ not analysable (n=164) 
♦ double entries (n=338)
Discontinued intervention (n=3 446; 42%) 
Analysed (n=8296)
Subgroup analysis
♦Per protocol analysis (n=4 850; 58%)
♦Intention to treat analysis (n=8 296; 100%)
Allocated to long-term follow-up (n=421)
Long-term follow-up Quality of life
Allocated to quality of life analysis (n=354)
Lost to follow-up (n=120; 29%)
Analysed (n=301; 71%)
Lost to follow-up (n=104; 29%)
Analysed (n=250; 71%)
Figure 1 Flow chart of study participants. Available data sets collected in 37 centers in Germany offering the program between July 1999 and December 2007.
1Two centers did not transfer their data due to data security reasons.
2Before starting analysis, the central database was purged of missing initial weight values and
double entries. The 52-week-intervention was discontinued in 41.5% for different reasons such as personal reasons (6.9%), no further appearance (6.5%), job-
related reasons (5.1%), disease/medical reasons (3.6%), financial reasons (3.4%), feeling of sufficient success (2.2%), familiar reasons (2.0%), mental/psychological
reasons (1.5%), exclusion by the program team (1.4%), weight regain (1.0%), product dissatisfaction (0.6%) or pregnancy (0.4%). In about 1/6 of cases, the reason
was unknown (7.2%).
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body weight in kg) and excess weight loss in percent
(100 Dweight loss in kg/initial body weight in kg   normal
body weight in kg), whereas normal body weight was defined
as the body weight corresponding to a BMI of 25kgm
 2.I n
all, 6759 out of 8296 participants’ (81%) WC was measured. In
these patients, the presence of a metabolic syndrome (MS) was
assessed according to the criteria of the International Diabetes
Federation. As drug intake was not monitored consistently,
only elevated laboratory parameters counted for the diagnosis
of MS. The waist-to-height ratio (WHtR) was calculated
according to the formula WHtR¼WC/body height.
In addition, two subgroup analyses were performed with
data derived from three centers. Data were pooled, as no
significant differences in weight change were observed
between the individual study centers. In the first subgroup
(n¼354), health-related quality of life (HRQOL) was assessed
using the SF36 score.
15 In a second subgroup of 301 out of
8296 participants (3.6%), long-term data on body weight
could be obtained and analyzed 2 (T3) and 3 years (T4) after
program start.
Statistical analysis
Values are presented as means and 95% confidence intervals
(95% CI), if not indicated otherwise. Time courses were
compared using the general linear model with repeated
measures and contrasts for case differentiation. The unpaired
two-samples t-test was employed for identification of base-
line gender differences. Frequencies were compared using
cross tables, according to the method of McNemar for time
courses, and w
2-test for analysis of gender differences.
P-values o0.001 were interpreted as statistically highly
significant (***), P-values between 0.001 and o0.01 as very
significant (**) and P-values between 0.01 and o0.05 as
significant (*). Analysis of the main data set was performed
using three approaches, the classical per-protocol analysis
(PP) and ITT, and the recently recommended multiple
imputation (MI) method in case of missing data, which
allows the ability to impute plausible values for the missing
data.
16 However, despite some advantages of the MI for
analysis of clinical trials, for example, on weight loss,
17 we
did not include thoroughly the MI analysis method in our
results, because it yielded results being almost identical to
those obtained by PP analysis. Obviously, employment of MI
to our data set resulted in particular positive results (Figure 2),
although literature suggests that the results would be
between those derived from PP and ITT/last observation
carried forward analysis. Moreover, according to sample size,
the clinical trial is statistically overpowered and therefore
does not necessarily demand imputation of missing data
from participant ‘dropouts.’ In the ITT analysis, the final
existent weight values of the dropouts were used according
to the last observation carried forward method. All analyses
Figure 2 Mean weight changes of subjects participating in the 52-week-weight loss program. (a). PP analysis in 4850 participants, (b) MI analysis in 8296
participants, (c) ITT analysis in 8296 participants and (d) dropout analysis in 3446 participants, who did not complete the protocol. Percentages indicated at the
right are RWLs at time points T2o rTend, expressed in percent of body weight at program start (T0).
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17.0 (IBM SPSS, Chicago, IL, USA) and Graph Pad Prism,
version 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Baseline characteristics
At study entry, 20% of the subjects emerged to have grade I
obesity (BMI 30–34; 9kgm
 2), 32% grade II obesity (BMI
35–39.9) and 47% grade III obesity (BMI 440). Of the patients
with obesity grade III, 10% had a BMI 450 and 2% 460.
Arterial hypertension was present in 3157 subjects (38%),
hypertriglyceridemia in 1684 (25%), hypercholesterolemia in
1168 (14%), elevated ALT in 793 (13%), pathological fasting
glucose in 728 (11%) and elevated creatinine (~41,
#41,2mgdl
 1) in 406 (6%). Only 24% of the participants
had no signs of obesity-associated diseases, according to this
assessment. More than half of the participants fulfilled the MS
criteria of the International Diabetes Federation. As expected,
obesity was more pronounced in patients with MS (mean
122.9kg, 95% CI, 122.1–123.7), compared with those without
MS (mean 114.9kg, 95% CI, 114.2–115.6; D1.5 BMI units,
Po0.001). Patients with arterial hypertension, diabetes or
elevated ALT values had a significantly higher BMI than those
with normal range values (D2.7 BMI units, D2.9 BMI units and
D1.2 BMI units, respectively; Po0.001). The baseline anthro-
pometric and clinical data at study entry of the 8296
participants are summarized in Table 1. Of 8296 recruited
participants, 3446 (42%) terminated the program before
52 weeks (Figure 1). Of those, 1818 (22% of all participants)
dropped out within the first 26 weeks. Then, 1627 subjects
(19%) dropped out after week 42. Reported reasons for
dropout ahead of schedule were manifold (Figure 1).
Change in body weight and other anthropometric measures
The overall response rate to OF52 expressed as RWL
calculated according to ITT analysis was 13.8% of the initial
body weight. The highest response rate of 14.6% occurred in
the subgroup of participants with an initial BMI of
40–50kgm
 2. According to PP analysis, an RWL of 20.4%
(T1) and 17.9% (T2) of total body weight (Po0.001) was
observed (Table 2 and Figure 2). Interestingly, even the preterm
dropouts not included in the PP analysis underwent a
significant weight reduction of in average 7%. In total, 82.1%
of the completers and 64.3% of all participants successfully
reduced initial body weight by 10% or more, corresponding to
the WHO definition of successful weight loss. A weight
reduction of at least 15% achieved 61.1% (PP analysis) and
47.6% (ITT analysis), respectively. Also the reduction in WC
was highly significant (Table 2). Recently, the WHtR has been
suggested as a better predictor of cardiovascular risk and
mortality than WC in obese individuals.
18 Therefore, we also
calculated WHtR and found, based on ITT analysis, that the
percentage of individuals with a normal WHtR o0.5 could be
enhanced from 0.4–9.0% (Po0.001). Within the first 6 months
of intervention (T0 T1), males were more successful than
females in terms of weight reduction, but also in terms of
reduction of BMI and WC (all Po0.001).
Change in blood pressure
Mean systolic blood pressure was reduced significantly from
141.1mmHg to 131.4mmHg (Po0.001), mean diastolic
blood pressure was reduced from 88.2mmHg to 80.9mmHg
(Po0.001) in subjects who completed the program (Figure 3).
The ITT analysis yielded a reduction of systolic blood
pressure by 8.0mmHg (Po0.001) and of diastolic blood
pressure by 5.9mmHg (Po0.001). According to these data,
more than 1000 individuals normalized their blood pressure
in the course of the program (PP analysis, 1026 participants
corresponding to 51% of the patients with hypertension at
start and ITT analysis, 1137 participants corresponding to
36%). As only a minority of the participants received drug
treatment at start (4%) and during the program (9%), either
because they did not consult a doctor or they refused drug
treatment, this effect is largely due to the weight reduction
and life style change and not because of pharmacologic
intervention.
Table 1 Study population baseline characteristics (means, 95% CI in brackets)
Parameter (unit) All subjects (n¼8.296) Females 73.7% (n¼6.111) Males 26.3% (n¼2.185)
Age (years) 42.4 (42.2–42.7) 41.8 (41.5–42.1) 44.2 (43.7–44.7)
BMI (kgm
 2) 40.8 (40.6–40.9) 40.3 (40.1–40.5) 42.1 (41.8–42.4)
WC (cm) 119.3 (118.8–119.7) 114.1 (113.8–114.5) 133.6 (132.9–134.4)
WHtR 0.700 (0.698–0.703) 0.686 (0.683–0.688) 0.741 (0.737–0.746)
Blood pressure (mmHg)
Systolic 141.1 (140.6–141.5) 138.8 (138.3–139.3) 147.4 (146.6–148.4)
Diastolic 88.2 (87.9–88.4) 87.3 (87.0–87.6) 90.6 (90.0–91.1)
Glucose (Ul
 1) 100.9 (100.1–101.8) 98.4 (97.6–99.3) 108.2 (106.3–110.3)
Cholesterol (mgdl
 1) 211.9 (211.0–213.0) 213.1 (212.0–214.3) 208.6 (206.6–210.5)
Triglycerides (mgdl
 1) 166.1 (163.7–168.6) 154.0 (151.5–156.6) 200.4 (194.5–206.3)
Abbreviations: BMI, body mass index; CI, confidence interval; WC, waist circumference; WHtR, waist to height ratio.
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diseases
Within 1 year of OF52, values of key laboratory parameters
were significantly reduced according to PP analysis, for
example, triglycerides (from 166.1–133.0mgdl
 1), cholesterol
(from 211.9–202.5mgdl
 1) and low-density lipoprotein–
cholesterol (from 131.1–105.6mgdl
 1), respectively (all
Po0.001). High-density lipoprotein–cholesterol increased
within the year from 52.5–57.9mgdl
 1 (Po0.001). Levels of
the liver enzyme ALT, which was elevated at program start in
men and less pronounced in women, decreased significantly
by 20% (Po0.001). Mean fasting glucose levels changed from
100.9–90.9mgdl
 1 (Po0.001). For uric acid, a mean reduc-
tion of 14% was observed (Po0.001). These changes resulted
in a significant decrease in the number of individuals with MS
and with obesity-associated diseases (Table 3). The predictive
value of baseline parameters (age, sex, height, weight, BMI,
WC, blood pressure, laboratory means) with regard to weight
Table 2 Weight loss during the 52-week-lifestyle intervention program
PP analysis All (n¼4851) Females (n¼3649) Males (n¼1202)
Weight T0 (kg) 118.4 (117.7–119.1) 112.4 (111.7–113.0) 136.7 (135.3–138.2)
Weight T1 (kg) 94.2 (93.6–94.8) 89.9 (89.3–90.5) 107.2 (105.9–108.4)
Weight T2 (kg) 97.3 (96.6–97.9) 92.8 (92.2–93.4) 110.8 (109.5–112.1)
D Weight T0 T1 (kg) 24.2 (23.9–24.5)*** 22.4 (22.1–22.7)*** 29.5 (28.8–30.2)***
RWL T0 T1 (%) 20.4 19.9 21.6
EWL T0 T1 (%) 52.5 52.2 52.8
D Weight T0 T2 (kg) 21.2 (20.8–21.5)*** 19.6 (19.2–19.9)*** 26.0 (25.2–26.8)***
RWL T0 T2 (%) 17.9 17.4 19.0
EWL T0 T2 (%) 45.8 45.8 46.8
D Weight T1 T2 (kg) +3.0 (2.8–3.2)*** +2.9 (2.7–3.0)*** +3.5 (3.1–3.9)***
Weight regain (%)
a 3.3 3.4 3.3
BMI T0 (kgm
 2) 40.8 (40.6–41.0) 40.4 (40.2–40.7) 42.1 (41.6–42.5)
BMI T1 (kgm
 2) 32.5 (32.3–32.7) 32.4 (32.2–32.6) 33.0 (32.6–33.3)
BMI T2 (kgm
 2) 33.6 (33.4–33.8) 33.4 (33.2–33.6) 34.1 (33.7–34.5)
D BMI T0 T1 (kgm
 2) 8.3 (8.2–8.4)*** 8.1 (8.0–8.2)*** 9.1 (8.9–9.3)***
D BMI T0 T2 (kgm
 2) 7.3 (7.2–7.4)*** 7.0 (6.9–7.2)*** 8.0 (7.7–8.2)***
WC T0 (cm) 118.8 (118.3–119.4) 114.1 (113.6–114.6) 133.5 (132.5–134.5)
WC T1 (cm) 99.7 (99.2–100.2) 96.2 (95.7–96.8) 110.4 (109.2–111.5)
WC T2 (cm) 102.0 (101.5–102.5) 98.5 (89.0–99.0) 112.6 (11.6–113.7)
D WC T0 T1 (cm) 19.1 (18.7–19.4)*** 17.7 (17.4–18.1)*** 23.3 (22.5–24.0)***
D WC T0 T2 (cm) 17.1 (16.7–17.4)*** 15.9 (15.4–16.2)*** 20.7 (20.0–21.5)***
WHtR T0 0.700 (0.697–0.702) 0.686 (0.683–0.689) 0.742 (0.737–0.748)
WHtR T1 0.587 (0.584–0.590) 0.579 (0.575–0.592) 0.612 (0.605–0.618)
WHtR T2 0.600 (0.598–0.603) 0.592 (0.589–0.596) 0.625 (0.619–0.631)
D WHtR T0 T1 0.110 (0.110–0.114)*** 0.107 (0.105–0.109)*** 0.129 (0.125–0.133)***
D WHtR T0 T2 0.100 (0.098–0.102)*** 0.095 (0.093–0.098)*** 0.115 (0.111–0.120)***
ITT analysis All (n¼8296) Females (n¼6111) Males (n¼2185)
Weight T0 (kg) 118.7 (118.1–119.2) 112.0 (11.5–112.6) 137.2 (136.1–138.3)
Weight TEnd (kg) 102.3 (101.8–102.8) 96.8 (96.3–97.3) 117.7 (116.6–118.9)
D Weight T0 TEnd (kg) 16.4 (16.1–16.6)*** 15.2 (14.9–15.6)*** 19.4 (18.7–20.1)***
RWL T0 TEnd (%) 13.8 13.6 14.1
EWL T0 TEnd (%) 35.6 35.8 34.7
BMI T0 (kgm
 2) 40.8 (40.6–40.9) 40.3 (40.1–40.5) 42.1 (41.8–42.4)
BMI TEnd (kgm
 2) 35.1 (35.0–35.3) 34.8 (34.6–35.0) 36.1 (35.8–36.4)
D BMI T0 TEnd (kgm
 2) 5.6 (5.5–5.7)*** 5.5 (5.4–5.6)*** 6.0 (5.8–6.2)***
WC T0 (cm) 119.3 (118.8–119.7) 114.1 (113.8–114.5) 133.6 (132.9–134.4)
WC TEnd (cm) 108.3 (107.8–108.7) 103.1 (102.6–103.5) 120.1 (119.2–120.9)
D WC T0 TEnd (cm) 11.0 (10.7–11.2)*** 10.4 (10.1–10.7)*** 12.6 (12.0–13.2)***
WHtR T0 0.700 (0.698–0.703) 0.686 (0.683–0.688) 0.741 (0.737–0.746)
WHtR TEnd 0.631 (0.629–0.634) 0.679 (0.616–0.622) 0.666 (0.661–0.671)
D WHtR T0 TEnd 0.064 (0.063–0.066)*** 0.062 (0.061–0.064)*** 0.070 (0.067–0.073)***
Abbreviations: EWL, excess weight loss in percent of excess body weight at start (equations see methods); ITT, intention-to-treat; PP, per protocol analysis;
RWL, relative weight loss in percent of total weight at start; T0, start of intervention; T1, week 26; T2,w e e k5 2 ;TEnd, last observation carried forward (LOCF) method
for ITT analysis; WC, waist circumference; WHtR, waist-to height ratio. ***Po0.001.
aExpressed as percent of weight at time point T1. Means, 95% CI in parenthesis,
are shown.
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meters were found when comparing succeeders (defined as
RWL 415% after 1 year) and others.
Adverse effects reporting
LCD programs have been shown to be effective; however,
potential adverse events must be considered. Therefore, all
reported adverse events were monitored and analyzed. Of
8296 participants, 96.2% reported no adverse events at all.
Most registered adverse events reported by 315 participants,
either related or unrelated to the intervention, were mild
and transient. However, two cases of death (0.02% of all
participants) were reported for which no clear statement
with regard to a possible relation to the intervention
program was made. The most common event during the
invention were alopecia (46 subjects, 0.6%), possibly caused
by micronutrient deficiency, and constipation (24 subjects;
0.3%), easily corrected by increased fluid and fiber intake.
The third most common event, likely related to obesity, were
biliary disorders such as colics, jaundice and cholecystitis (18
subjects; 0.2%) caused of bile stones or sludge. In 14
participants, a cholecystectomy was necessary. Questionably
related to obesity or to the intervention program are
malignancies such as breast cancer, lung cancer and color-
ectal cancer (4 subjects, 0.05%). All other events were mild
and occurred in less than 0.1%; they were either unrelated to
the program, or so rare that no conclusion could be made.
Long-term outcome data
In a subgroup of 301 subjects, long-term data on body weight
beyond the intervention period of 1 year could be obtained
and analyzed for up to 3 years (Figure 4). The baseline
parameters of these patients (44.7 years old, BMI 40.1kgm
 2,
RWL 19.2%, excess weight loss 46.9%, all means) matched
the overall study population during the 1-year-intervention
program. The data show that even 3 years after start of
intervention, the extent of weight loss remained statistically
still highly significant, despite a relative weight gain of 15.1%
(95% CI, 12.8–17.4) 2 years after program termination. The
mean weight loss after 3 years was 5.9kg (95% CI, 3.7–8.1),
RWL 4.2% of initial body weight (95% CI, 2.3–6.0).
Quality of life
HRQOL was assessed in 325 subjects using the SF36
questionnaire. At the end of the 1-year-intervention –
program, all parameters indicating physical and psychological
Figure 3 Change in blood pressure in participants of a 52-week-weight loss
program. Number of patients with hypertension (systolic 4140mmHg or
diastolic 490mmHg) and corresponding percentages based the whole study
population are shown. (a) PP analysis, (b) ITT analysis. TEnd in the ITT analysis
was calculated using the last observation carried forward method method. All
percentages at time points T1, T2 and TEnd were significantly different
compared with T0( a l lPo0.001).
Table 3 Improvement of obesity-related comorbidities in the course of the
52-week-lifestyle intervention program
nT 0[%] T1/TEnd [%] T2 [%]
Metabolic syndrome (IDF criteria)
PP (n (%)) 3893 54% 19%*** 23%***
ITT (n (%)) 6759 57% 30%***
Hypertriglyceridemia
PP (n (%)) 3929 24% 11%*** 14%***
ITT (n (%)) 6734 25% 17%***
Hypercholesterolemia
PP (n (%)) 3026 17% 13%*** 14%
ITT (n (%)) 5380 14% 12%**
Fatty liver disease
a
PP (n (%)) 3504 17% 5%** 5%
ITT (n (%)) 6102 13% 9%***
Diabetes
a
PP (n (%)) 3814 11% 3%*** 4%***
ITT (n (%)) 6616 11% 6%***
Renal failure
a
PP (n (%)) 3940 7% 7% 7%
ITT (n (%)) 6774 6% 8%
Abbreviations: IDF, International Diabetes Federation; ITT, intention-to-treat;
PP, per protocol analysis.**Po0.01. ***Po0.001 compared with T0 values
at T1/TEnd, or compared with T1 values at T2.
aFor definition of disease, see
Materials and methods.
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baseline data (Figure 5). Even 3 years after program start, most
of those parameters, for example, physical functioning
(þ11.6%, Po0.001), general health (þ7.3%, Po0.01),
vitality (þ4.7%, Po0.001) and mental health (þ7.3%,
Po0.001), still indicated significant ameliorations compared
with initial values.
Discussion
Here, we show in a large cohort of patients with grade I–III
obesity that a non-surgical obesity therapy program per-
formed in specialized centers under ambulatory conditions
over 52 weeks is highly effective in reducing body weight
and obesity-associated diseases after 12 month. According to
the WHO definition of successful weight loss (410% loss of
initial body weight), the grand majority of participants (81%
according to PP and 64% according to ITT analysis) were
successful after 1 year of treatment. Of the successful people,
2/3 achieved a weight loss of 415%, independent of the type
of statistical analysis, a result not documented before by
other non-surgical intervention programs. Moreover, WC
was substantially reduced (by 21cm in males and 16cm in
females), which could be of major clinical relevance, because
already a 3cm reduction of WC results in significant
improvement of cardiometabolic risk factors.
19 Interestingly,
the effects were more pronounced in male than in female
participants. This gender difference is most likely due to the
fact that (1) males entered the program with higher body
weights and higher BMI and (2) an energy intake of 800kcal
per day means a more pronounced restriction for males than
for females.
10
The beneficial effects of the program on body weight were
not restricted to particular ranges of initial body weight.
Weight reduction was most pronounced in participants
with an initial BMI of 440–50kgm
 2, but the effects were
almost as good in patients with moderate obesity (BMI
30–40kgm
 2) and in patients with severe obesity (BMI
450kgm
 2) who are often referred for bariatric surgery. Not
only anthropometric, but also other risk parameters defining
the MS were strongly reduced. Of particular importance is
the pronounced effect of the intervention on blood pressure,
which confirms previous reports.
20,21 Among patients with
hypertension at program entry, blood pressure was reduced
to an extent similar to that achieved by pharmacological
treatment.
21 These data strongly suggest that a non-surgical
obesity therapy program performed under medical super-
vision not only reduces risk of metabolic diseases, but also
has substantial drug cost-saving effects.
Figure 4 Long-term weight curves over 3 years. The interdisciplinary weight
loss program was terminated after 12 months. Means (±95% CI) of data
obtained from three centers at program start (T0), at program end (T1) and
12 months (T2) and 24 months (T3) later, are shown. In total, 301 unselected
data sets were analyzed for which T0, T2 and T4 data were available. Of these
data courses, measurements at T3 were available in 114 cases.
yT4 data ranged
between 30–39 months (95% CI, mean 36.4 months). ***Po0.001.
Figure 5 Long-term outcome of HRQOL in patients who participated in an
interdisciplinary weight loss program (means±95% CI). (a). Physical aspect of
health according to SF36. (b). Psychological aspect of health according to
SF36. Time points of data collection were at T0 (month 0; n¼354), T2 (month
12; n¼272) and T4 (month 36±6 after program entry; n¼250). Statistics
*Po0.05, **Po0.01, ***Po0.001 when compared with program start (T0).
German reference population (see SF36 manual).
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included all participants who started the program without
selection during a 8.5-year-period of evaluation, which
moderates the drawback because of lack of a randomized
controlled study design for obvious technical and ethical
reasons. Results might be biased if only patients from
centers with above average therapeutic care are included in
evaluations. This has also to be taken into account when
comparing the results with bariatric surgery, as only a
fraction of all operated patients are evaluated in studies.
The relevance of our data is further strengthened by three
additional findings: (1) a clear association between improve-
ment of markers of physical health and HRQOL, (2) signs of a
sustained benefit beyond the intervention period of 1 year
and (3) no relevant adverse effects after a careful analysis of
safety over 10 years of experience.
Most importantly, our data also show that the weight loss
achieved after 6 months of treatment were stabilized in most
cases until the end of the program. Minor weight gain within
week 27–52 of treatment was approximately 3kg. Rapid
weight gain within weeks (‘yo-yo-effect’) was not observed.
The question often asked is whether a non-invasive treat-
ment can maintain its effect beyond the 1-year-treatment
period. In the past, the expectations were high in this
respect, although no defined intervention followed the
1-year-program. Interestingly, we found in a subgroup of
301 participants from whom long-term data were available
for analysis, that weight loss based on the initial body weight
is still statistically highly significant and clinically substan-
tial after 3 years of observation.
Concerning safety, a non-surgical intervention is generally
preferable to an invasive therapy, because it does not alter
the integrity of the digestive tract and has no irreversible
consequences. Indeed, the few adverse events we saw were
thoroughly harmless and infrequent, except the risk of
biliary disease among people who lose weight through LCD,
because of the missing stimulus for gallbladder contraction.
However, not only restriction diets, but also obesity per se
may account for the enhanced risk of cholelithiasis and
sludge,
22,23 promoted by an increased hepatic secretion of
cholesterol.
24 The risk rises linearly with increasing obesity
25
and is particularly high in women with extreme obesity.
26
Two cases of death (0.02%) and five cases of malignant
diseases (0.05%) occured within the year of intervention
among 8296 participants. Taken into consideration that
obesity was found to be associated with enhanced cancer
incidence
27 and mortality,
28 the two reported cases of death
do not at all suggest an increased mortality related to the
intervention program.
Our data revealed that OF52 is for now almost similarly
effective as several invasive treatment options for obesity
such as banding or vertical gastroplasty, as reported in the
Swedish Obese Subjects study in which individuals with
similar initial BMI were included.
29,30 In completers, the
average excess weight loss after our non-surgical interven-
tion was 53%, which is close to the overall weight loss of
61% reported in a meta-analysis about bariatric surgery.
31
Only the more invasive gastric bypass seems to be clearly
more effective than the non-surgical obesity therapy
program tested here.
Most recently, the randomized controlled Louisiana Obese
Subjects Study
32 showed that a 24-month-non-surgical
primary care practice program with LCD (890kcal per day)
for up to 12 weeks, meal replacements and choice of
pharmacotherapy is highly effective in a primary care
setting. However, although participants in our study were
less obese than in LOSS, RWL at 1 year was higher after OF52
(17.9%), compared with LOSS (13.1%). The higher effective-
ness we achieved could be because our program is more
precisely structured and contains more intensive external
therapeutic support, combined with regular exercise pro-
gram and a complete full meal replacement for 12 weeks for
all participants. Another primary care approach with similar
results as reported in the LOSS study has been published
from the UK some years earlier.
33 Such data indicate that
structured interdisciplinary programs performed in specia-
lized centers might be more effective than primary care
approaches.
Our data indicate that the OF52 program is more effective
than primary care practice program within an observation
time of 12 month. Compared with other medically super-
vised proprietary programs, the OF52 outcome data are
comparable to what has been reported for other programs
when looking at the 3–6 month data (RWL 20% here versus
15–25% in Tsai and Wadden
8). However, OF52 is definitively
more effective after 12 month (18% here versus 8–9% in Tsai
and Wadden
8). Interestingly, the advantage of OF52 seen
after 12 month seem to disappear after 3 years (4.2% here
versus 7% in Tsai and Wadden
8), suggesting that without
continuation of treatment, the effects will fade away with
time. At present, it is unclear if this long-term weakness of
non-surgical programs, and to some extent also of surgical
interventions, is unavoidable or just a result of the lack of
appropriate follow-up programs after the initially successful
intervention.
The advantages of conservative programs (higher accep-
tance rate, low rates of adverse events and lower costs) are
contrasted by reports suggesting higher relapse rates,
compared with those after bariatric surgery. However, our
data confirm previous reports showing that non-surgical
interventions, even though they differed to the program we
accomplished here, are still effective up to 5 years after start.
9
Most importantly, the rate of weight loss achieved by using
the LCD within the first weeks of the program seems to
be not only highly motivating, but also the most effective
non-surgical method of sustained weight loss.
11 According to
our preliminary long-term data, about 30% of the patients
were successful regarding weight reduction over a time
period of 3 years. Of them, 7% successfully maintain or even
further reduce their weight after intervention without
further support and 22% of the participants slowly regain
weight, but still remain clearly below their initial weight.
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consumption of meal replacements were identified as most
relevant factors associated with success.
34 Interestingly, even
after surgical intervention, a certain weight gain is ob-
served.
29,30 The relative weight gain 3 years after lowest
recorded weight is about 5% in surgery studies and 15% in
our study, indicating the necessity of effective weight
maintenance programs that must follow all primary inter-
ventions, even those with 12 months initial duration. On
the other hand, bariatric surgery, depending on the extent of
malabsorption induced, is definitely less prone to the risk of
weight regain compared with all non-surgical intervention
programs. To which extent this major problem of even
initially successful non-surgical programs like OF52 can be
attenuated by appropriate follow-up interventions needs to
be studied in future trials.
In conclusion, we demonstrated that defined non-surgical
intervention programs such as the OF52 program could be
highly effective in reducing body weight and risks of obesity-
associated diseases. Therefore, we propose such an approach
as promising choice for the primary treatment of obesity in
adults and confirm it to be the first option before consider-
ing bariatric surgery.
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